Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells $43,637.15 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 1,457 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $29.95, for a total transaction of $43,637.15. Following the transaction, the general counsel directly owned 18,086 shares in the company, valued at $541,675.70. This represents a 7.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $31.00 on Friday. The firm has a market cap of $1.93 billion, a PE ratio of -11.03 and a beta of 1.17. The stock’s fifty day moving average price is $31.93 and its two-hundred day moving average price is $32.34. Stoke Therapeutics, Inc. has a one year low of $11.17 and a one year high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.01. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%.The firm had revenue of $6.23 million during the quarter, compared to the consensus estimate of $6.48 million. Sell-side analysts expect that Stoke Therapeutics, Inc. will post -3.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Janus Henderson Group PLC grew its position in Stoke Therapeutics by 333.8% during the 4th quarter. Janus Henderson Group PLC now owns 1,450,933 shares of the company’s stock valued at $46,031,000 after purchasing an additional 1,116,452 shares during the last quarter. State Street Corp lifted its stake in shares of Stoke Therapeutics by 75.2% in the fourth quarter. State Street Corp now owns 2,498,049 shares of the company’s stock worth $79,288,000 after buying an additional 1,072,176 shares in the last quarter. Corient Private Wealth LLC purchased a new stake in shares of Stoke Therapeutics during the second quarter valued at approximately $7,489,000. Troluce Capital Advisors LLC purchased a new stake in shares of Stoke Therapeutics during the first quarter valued at approximately $21,255,000. Finally, BVF Inc. IL increased its position in shares of Stoke Therapeutics by 36.7% during the fourth quarter. BVF Inc. IL now owns 2,265,674 shares of the company’s stock valued at $71,912,000 after acquiring an additional 608,578 shares in the last quarter.

Analysts Set New Price Targets

Several brokerages recently weighed in on STOK. Wall Street Zen cut shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Chardan Capital reiterated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 18th. Weiss Ratings cut shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research report on Monday, May 11th. BTIG Research reiterated a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a report on Monday, May 11th. Finally, Needham & Company LLC raised their price objective on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $41.83.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.